The US Food and Drug Administration has issued an urgent safety correction affecting Automated Impella Controller units manufactured by Abiomed due to identified hardware vulnerabilities that pose significant risks to patient safety. The defects could potentially delay or completely interrupt hemodynamic support during critical cardiac procedures, threatening patients who depend on these life-sustaining devices.
The Automated Impella Controller serves as the primary control interface for Impella heart pumps, which provide temporary mechanical circulatory support for patients with severe cardiac conditions requiring intervention. According to the FDA’s safety communication, certain AIC units contain hardware issues that may cause unexpected device behavior precisely when patients are most vulnerable.
Healthcare facilities utilizing affected units must take immediate action by contacting Abiomed to implement mandatory hardware updates. The agency emphasizes the urgency of these corrective measures to ensure uninterrupted cardiac support and protect patient outcomes during high-risk procedures. Read the full article on GMJ Newsroom.
Was this article helpful?
